Homepage > Company > Media > Pharma News > 2024 > Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease

Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.

According to a release from Vivet Therapeutics, GATEWAY is a nonrandomized, open-label study conducted across several clinical sites in the United States, United Kingdom, Germany and Denmark. The trial seeks to assess the safety, tolerability and pharmacological activity of a single IV infusion of VTX-801, a novel, investigational gene therapy, at increasing dose levels in adult patients with Wilson’s disease.

Initiation of cohort 2 followed the successful completion of cohort 1 and subsequent approval from an independent data monitoring committee to proceed, the company said.

“We are encouraged by the initial safety, histological and pharmacodynamic data that VTX-801 has demonstrated to date, and we are pleased that the first patient has been successfully dosed in Cohort 2 in the GATEWAY clinical trial,” Jean-Philippe Combal, CEO at Vivet Therapeutics, stated in the release. “2024 is shaping up to be a transformative year for Vivet and its gene therapy platform and we look forward to providing further data on our GATEWAY clinical trial at upcoming scientific conferences.”

April 15, 2024

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.